Sugiyama et al. reported the renoprotective effect of SGLT2 inhibitor therapy in patients with type 2 diabetes and renal dysfunction (CKD stages 3b-4) in a relatively small number of study subjects (n = 42), including 5 patients who received tofogliflozin [31]. The gene discussed is SLC5A2; the disease is chronic kidney disease.